Zotarolimus

Zotarolimus (ABT-578) is a derivative of Rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis[1][2].

Product Specifications

CAS Number

[221877-54-9]

Product Name Alternative

ABT-578; A 179578

UNSPSC

12352005

Target

Drug Derivative

Type

Reference compound

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Zotarolimus.html

Purity

98.59

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CO[C@H]1[C@@H](N2C=NN=N2)CC[C@@H](C[C@H]([C@@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H]3C)C)=O)OC)O)\C)C)=O)([H])OC([C@@](CCCC4)([H])N4C(C([C@](O[C@]5([H])C[C@@H](/C(C)=C/C=C/C=C/3)OC)([C@@H](CC5)C)O)=O)=O)=O)C)C1

Molecular Formula

C52H79N5O12

Molecular Weight

966.21

References & Citations

[1]Sandra E Burke, et al. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev. 2006 Jun 3;58 (3) :437-46.|[2]Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.